Skip to content

Lipid-lowering effects of ACTH

Lipid-lowering effects of ACTH

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-005438-11-IS
Enrollment
40
Registered
2005-12-05
Start date
2005-12-29
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy male volunteers

Interventions

Trade Name: Synacthen Depot Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use

Sponsors

Univ. of Iceland, Dept. Pharmacol.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Healthy, male, age 18-60 years. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: History of endocrine-, renal-, malignant or inflammatory disease. Treatment with a drug that affects blood-lipids. Allergy for Synacthen Depot og any other drug containing ACTH. Cooperation problems.

Design outcomes

Primary

MeasureTime frame
Main Objective: To establish the blood-lipid lowering effetcts of ACTH. To find the most appropriate dosing interval that gives a steady lipid-lovering effect.;Secondary Objective: Recording of adverse reactions.;Primary end point(s): Serum concentration of LDL-cholesterol and apolipoprotein-B.

Countries

Iceland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026